对认知衰退和痴呆症的等离子体蛋白质组学 - 一项东南亚队列研究
Ming Ann Sim1,2,3, James D Doecke4, Oi Wah Liew5,6
1Departments of Pharmacology and Psychological Medicine, Memory Aging and Cognition Centre, National University of Singapore, Singapore, Singapore.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|February 25, 2025
概括
血蛋白签名可以预测认知衰退和痴呆症. 新加坡队列中的这些发现在高加索队列中得到了验证,为神经退行性疾病提供了潜在的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 蛋白质组学是指蛋白质组学.
- 生物标志物发现发现
背景情况:
- 血蛋白质学对认知衰退和痴呆症的预后效用在具有高脑血管疾病 (CeVD) 负担的东南亚人群中尚未得到充分研究.
- 脑血管疾病是认知障碍的一个重要因素.
研究的目的:
- 研究血蛋白质学对认知衰退和痴呆症的预后价值.
- 识别可预测的蛋白质特征,并在不同的队列和生物流体中验证它们.
主要方法:
- 分析了一组新加坡记忆诊所队列 (n=528),随访时间为4年.
- 分析了1441种血蛋白质,并确定了12种蛋白质的认知衰退特征.
- 外部验证是使用来自高加索队列的脑脊液蛋白质组数据进行的.
主要成果:
- 12种蛋白质的签名显著预测了认知衰退 (q < 0.05),10种蛋白质预测了发生痴呆症 (q < 0.05).
- 血蛋白和临床因素的组合模型改善了预测准确度 (AUC 0.62 至 0.85).
- 四种血标记物 (GFAP,NEFL,AREG,PPY) 在一个独立的高加索队列的脑脊液中被复制.
结论:
- 识别的预后性血蛋白签名在不同的生物矩阵 (血和脑脊液) 中提供了强大的信号.
- 这些蛋白质代表了痴呆症和认知衰退的潜在机械目标.
- 进一步的研究是有必要的,以探索治疗影响.
相关概念视频
Dementia
88
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
88
Alzheimer's Disease: Overview
422
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
422


